GI Dynamics, Inc.

Equities

GIDYL

AU000000GID7

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-99.33%

2023	GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India	CI
2022	GI Dynamics, Inc. Announces Final Data from the ENDO Trial, Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity	CI

GI Dynamics, Inc. Presents Worldwide Endobarrier Registry Data for 871 Patients at EASD 2019

September 19, 2019 at 06:28 pm EDT

GI Dynamics® Inc. announced positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry evaluating the benefit: risk of EndoBarrier, presented by Katharina Laubner, M.D. of the University of Freiburg. The data was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain on 19 September 2019. The poster 'Duodenal-jejunal Bypass Liner (DJBL) for Treatment of Type 2 Diabetes and Obesity - The Risk: Benefit Ratio from the Worldwide EndoBarrier Registry in 871 Patients', demonstrates the safety and efficacy profile that EndoBarrier provides patients diagnosed with type 2 diabetes and/or obesity. The ABCD Worldwide EndoBarrier Registry, led by Robert Ryder, M.D. of City Hospital in Birmingham, U.K, collected data from 28 centers in eight countries throughout the world.

Latest news about GI Dynamics, Inc.

GI Dynamics, Inc. Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India	23-02-13	CI
GI Dynamics, Inc. Announces Final Data from the ENDO Trial, Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity	22-06-15	CI
GI Dynamics Inc. Announces Approval of the I-STEP Clinical Study in India	22-01-31	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-07	CI
Gi Dynamics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-12	CI
GI Dynamics, Inc. Auditor Raises 'Going Concern' Doubt	21-03-11	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Treasurer and Secretary	21-01-15	CI
GI Dynamics, Inc. Announces Termination of Charles Carter as Chief Financial Officer	21-01-15	CI
Gi Dynamics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-10	CI
GI Dynamics, Inc. Announces CEO Changes	20-11-06	CI
GI Dynamics, Inc. Announces Management Changes	20-11-06	CI
GI Dynamics, Inc. Announces Executive Changes	20-10-26	CI
GI Dynamics, Inc. Announces the Appointment of Joseph Virgilio as its Chief Operating Officer	20-10-15	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	20-09-03
GI Dynamics, Inc. Announces Board Resignations	20-08-10	CI
Gi Dynamics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-07	CI
GI Dynamics, Inc. announced that it has received $0.5 million in funding from Crystal Amber Asset Management Limited	20-08-03	CI
GI Dynamics, Inc. announced that it expects to receive funding from Crystal Amber Asset Management Limited	20-08-02	CI
GI Dynamics, Inc. announced that it expects to receive $9.25 million in funding from Crystal Amber Asset Management Limited	20-07-19	CI
Transcript : GI Dynamics, Inc. - Shareholder/Analyst Call	20-06-20
GI Dynamics, Inc. announced that it has received $0.75 million in funding from Crystal Amber Asset Management Limited	20-06-17	CI
Gi Dynamics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-06	CI
GI Dynamics, Inc. Enters into Sixth Amendment to the Senior Secured Convertible Promissory Note	20-03-31	CI
GI Dynamics, Inc. Announces Change to Board of Directors	20-03-29	CI
GI Dynamics, Inc. Auditor Raises 'Going Concern' Doubt	20-03-26	CI

Chart GI Dynamics, Inc.

Duration

Period

More charts

Company Profile

GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.

Sector

More about the company